Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Emergent Biosolutions ( (EBS) ) is now available.
On April 16, 2026, Emergent BioSolutions Inc. refinanced its debt structure by entering a new $150 million term loan with OrbiMed and amending its asset-based revolving credit facility with Wells Fargo. The new term loan, fully drawn at closing, carries Term SOFR plus 6.25% interest, matures as late as April 16, 2031, is secured by first- and second-lien collateral, and includes a $75 million delayed draw feature and an uncommitted incremental facility tied to leverage and EBITDA.
Proceeds from the new term loan, together with cash on hand, were used to repay and terminate the prior credit agreement with Oak Hill Advisors dated August 30, 2024. In parallel, Emergent reduced its ABL revolving commitment from $100 million to $50 million while extending its maturity to April 16, 2031 and loosening certain covenants, aligning both facilities with quarterly leverage tests and mandatory prepayment provisions tied to asset sales, excess cash flow and new indebtedness.
The refinancing is expected to reduce annual interest expense by about 200 basis points on the $150 million term loan and to extend key maturities by roughly five years, supporting Emergent’s multi-year transformation and turnaround plan initiated in 2024. Management highlighted that the combination of less restrictive covenants, expanded incremental debt capacity and extended maturities enhances liquidity and financial flexibility, positioning the company to stabilize its balance sheet and pursue growth and business development opportunities while continuing to lower its overall debt profile.
The most recent analyst rating on (EBS) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.
Spark’s Take on EBS Stock
According to Spark, TipRanks’ AI Analyst, EBS is a Neutral.
EBS scores in the low-50s primarily due to improving (but still volatile) financial performance—strong 2025 cash flow and a return to profitability are tempered by multi-year revenue decline and elevated leverage. Technicals are a notable drag with price below key moving averages and a negative MACD. Valuation is reasonable at ~12.6x earnings, while the earnings call balances strong operational progress against softer 2026 profitability guidance and non-recurring 2025 benefits.
To see Spark’s full report on EBS stock, click here.
More about Emergent Biosolutions
Emergent BioSolutions Inc., based in Gaithersburg, Md., operates in the biopharmaceutical industry with a focus on medical countermeasures and preparedness products. The company develops and supplies protective and life-saving solutions against public health threats including smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies for governments and communities worldwide.
Average Trading Volume: 891,557
Technical Sentiment Signal: Strong Sell
Current Market Cap: $447.2M
For detailed information about EBS stock, go to TipRanks’ Stock Analysis page.